1:00 pm2018
Sponsored by

Discovering the Missing Link between my Rare Disease and an Olympic Athlete


Emery-Dreifuss Muscular Dystrophy Patient Advocate

Head of Lab; Clinical Genomics and Personalized Medicine Specialist,

Deputy Head of Clinical Services,

In this webinar, Jill Viles, an Iowa mother with no clinical training, shares her story of how she self-diagnosed her rare condition, a muscle-wasting disease caused by a mutation in the LMNA gene. She will also discuss how she discovered that a mutation in the same gene is the underlying cause for the excess muscle phenotype exhibited by Canadian Olympic hurdler Priscilla Lopes-Schliep. 

Members of Congenica's clinical team will also discuss their identification of a potential modifying gene, SMAD7, which may contribute to Jill’s alternative phenotype, and how these are being used to further research the cause of her disease.

This webinar will cover:

  • Jill's steps to discovery and how she first started working with Congenica
  • How Congenica found the potentially modifying variant
  • The SMAD7 gene mutation, and how Sapientia can be used to make similar diagnoses
  • How Jill is acting on this information and looking to the future
Sponsored by

Assistant Professor, Center for Biomarker Research and Precision Medicine, School of Pharmacy, Virginia Commonwealth University

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Studies of DNA methylation provide a promising route to gain further insight into many complex phenotypes, but detailed biological knowledge linking specific methylation sites to phenotypes is lacking, making MWAS critical. Whole genome bisulfite sequencing (WGB-seq) provides comprehensive coverage of the methylome, but is not yet practically feasible with the sample sizes required for MWAS. This limitation may explain why MWAS is commonly performed using microarray-based technologies, which assay only a very small fraction of the methylome.

Comparisons show that optimized MBD-seq approximates the coverage obtained with WGB-seq, but this performance is achieved at a fraction (~5%) of the reagent costs for WGB-seq, bringing it within the approximate price point of array-based methods. The MBD-seq protocol also allows for as little as 5-50 ng of high-quality genomic DNA as input, which allows for many sample types of limited availability to be assayed.

In this webinar, Karolina Åberg of Virginia Commonwealth University will present findings from MWASs of major depressive disorder and childhood trauma using DNA from brain, whole blood, and blood spots to provide a proof of concept that MBD-seq based MWAS can shed light on disease etiology and identify potential clinical biomarkers.

Sponsored by

Laboratory Specialist, Clinical Genetics, University Medical Center Utrecht (UMCU)


This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

The current standard of care in genomics diagnostics laboratories is advancing toward array testing and whole exome sequencing on a single sample. Additionally, labs are shifting to the analysis of all molecular events for a patient sample – whether structural (CNVs, deletions, duplications, LOH regions, translocations) or molecular (SNPs, insertions, deletions). Labs do this because they are confident the diagnostic yield of combined CNV / NGS analysis exceeds that of each individual assay type, making 1+1=3.

Moreover, historically, the cytogenetics lab and the molecular lab were separate domains, within different groups at the lab or hospital. Cartagenia Bench Lab software, which was acquired by Agilent in 2015, catered to these different customer types with separate applications. While labs that did both arrays and sequencing could make the modules talk together and collaborate, they were not tightly integrated.

Today, with Alissa Interpret, the next evolution of Cartagenia Bench Lab recently released by Agilent, array data and WES data can now be integrated for a single patient sample, allowing for combined CNV/SNV analysis on a single workflow platform.

In this webinar, Ellen van Binsbergen, a laboratory specialist in clinical genetics at the University Medical Center Utrecht (UMCU) in The Netherlands, will share how Alissa Interpret was used in a case of multiple skeletal abnormalities to assess data from CNV analysis via SNP array and from WES analysis. By jointly triaging, classifying, and curating molecular and structural variants, she will show how UMCU was able to pinpoint variants inherited from the father AND deletions in the maternal allele – all yielded from a single sample, on one platform.

Sponsored by
1:00 pm2018
Sponsored by
Dovetail Genomics

Enabling Non-Model Organism Genomics with Multi-Dimensional NGS Datatype


PhD Student,
Petrov and Hadly Labs, Department of Biology, Stanford

Director of Product Management,
Dovetail Genomics

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research. Learn about some of the applications for this datatype and specifically how it helps create high-quality assemblies to overcome challenges of working with non-model organism genomes.

This webinar will highlight three projects where proximity ligation technology and scaffolding software were used to create high-quality and highly contiguous genome assemblies for different organisms. Our speakers will also discuss the scientific discoveries enabled by these high-quality genome assemblies.

Join this webinar to:

  • Learn how proximity ligation technology works and the applications for this multi-dimensional NGS datatype from cancer research to genome assembly
  • Hear how proximity ligation overcomes one of the main challenges of studying non-model organisms: being able to easily generate high-quality and contiguous genome assemblies
Sponsored by

Laboratory Manager, Central Lab in Igenomix, Valencia (Spain)

Senior Product Manager, Labcyte

This webinar will discuss how acoustic liquid handling can reduce the time and costs for labs performing carrier screening with next-generation sequencing.

Pere Mir Pardo of Igenomix will provide an overview of his company's Carrier Genetic Test (CGT), which uses NGS to assess a couple's carrier status for 600 Mendelian diseases.

In 2017, Igenomix adopted the Labcyte Echo 525 Liquid Handler for NGS library preparation. Dr. Mir Pardo will share how the new technology has enabled the reduction of the hands-on time for the CGT protocol, ultimately leading to a reduction in costs.

From October 2015 through December 2016, Igenomix analyzed 6,156 samples using the conventional NGS protocol. The Echo system was introduced into the laboratory in January 2017 and from then until July 2017 a total of 4,277 samples were analyzed using the Echo system protocol. Results of both protocols are similar in terms of sensitivity (0.9858) and specificity (0.9997) of mutation detection.

Iain Russell will present an overview of acoustic droplet ejection technology, describe the benefits of acoustic liquid handling for Genomics applications and provide a review of how the Echo is being utilized in for a variety of applications common to Genomics labs.

Attendees of this webinar will gain a deeper understanding of the features and benefits of acoustic liquid handling. Additionally, attendees will learn how NGS-based expanded CGT analysis constitutes a powerful tool to predict risk for Mendelian diseases, as well as how the Echo system makes the test more affordable and widely available to a higher number of patients.

Sponsored by
1:00 pm2018
Sponsored by

Applications and Challenges of Using ctDNA as Non-Invasive Tumor Markers


Manager, Scientific Affairs, Agena Bioscience 

Liquid biopsies are becoming increasingly important for the detection of actionable mutations in cancer due to tumor heterogeneity as well as the practical limitations of invasive tissue biopsies. Recent technological developments enable the use of circulating tumor DNA (ctDNA) as cancer biomarkers as a non-invasive complement and potentially even substitute for tissue biopsies.

This webinar will discuss the current research applications of ctDNA in cancer detection with potential for improved therapy guidance and monitoring. Critical challenges impeding liquid biopsy analysis and ways to overcome these challenges will also be discussed.

Sponsored by

Professor, Hematology, Medical School of Sorbonne University, Paris; Head of the Hematology Laboratory, Saint-Antoine Hospital 

This webinar will share details from a study at the Saint-Antoine Research Center, Sorbonne University to test the feasibility of a high-sensitivity, clone-specific strategy for evaluating minimal residual disease (MRD) in acute myeloid leukemia (AML).

AML is a genetically heterogeneous group of blood malignancies. Some specific translocations or mutations, such as t(8;21), inv(16), or NPM1 mutations, can serve as markers of treatment response, or detection of MRD. However, most AMLs harbor several mutations ordered in time to form the founding clone and subsequent linear or branching subclones. Improving the tools for a clone-specific, multi-target detection of MRD may be of particular importance in the future.

In this webinar, François Delhommeau, of Saint-Antoine Research Center will discuss a research study to test such a strategy in a retrospective cohort of 69 AML cases. Delhommeau and colleagues established the clonal architecture of each AML using standard cytogenetic and molecular assays, as well as targeted next generation sequencing (NGS). From this, they designed a clone-specific strategy based on fluorescent in situ hybridization (FISH) and high-sensitivity NGS (Haloplex HS) to detect chromosomal aberrations and mutations, respectively, in follow-up samples.

The combination of these techniques allowed the team to track chromosomal and genomic lesions down to 0.5% of the cell population in follow-up samples. By using these techniques, they found that 65 out of 69 cases were evaluable at several time points of follow up. Moreover, they observed that initiating events, such as DNMT3A or TET2 mutations, often persist, and appear not to be appropriate markers to predict short term relapse when considered in isolation from other factors. In contrast, the persistence of several lesions in more than 0.4% of the cells from remission samples may be predictive of lower leukemia-free and overall survivals.

Although larger prospective studies are needed to confirm these results, the data that Dr. Delhommeau will share show that a multi-target, clone-specific, minimal residual disease follow-up strategy may be feasible in the vast majority of AML cases.


Sponsored by
Recent GenomeWebinars
11:00 am2018
Sponsored by

A Practical Guide to Clinical Genomics Assay Validation


Gnosity Consults

SeraCare Life Sciences

This webinar walks through key considerations and helpful guidelines to accelerate next-generation sequencing (NGS)-based clinical genomics assay validation for less money and greater confidence in results.

NGS has revolutionized how assay developers, laboratories, and clinicians are diagnosing, treating, and managing disease. But before a clinical genomics assay can help guide patient care, it must be thoroughly validated. While validation principles are universal, the complexities of NGS can make the process a daunting task. In this webinar, clinical genomics expert Dr. Bob Daber uses real-world examples to highlight how highly multiplexed, patient-like biosynthetic reference materials offer substantial time and cost advantages over traditional materials and methods.

View this webinar to learn:

  • Specific ways you can save time and money while thoroughly validating an NGS-based clinical genomics assay
  • Validation best practices from leading clinical genomics laboratories
  • How to navigate the many guidelines and requirements of the various authoritative bodies for clinical genomics testing
Sponsored by
11:00 am2018
Sponsored by
Oracle Health Sciences

Improved Clinical Decision Support via Integrated Genomic and Clinical Data Sources


Research Scientist,
Mayo Clinic

Field Scientist and Strategist,
Oracle Healthcare

This webinar covers best practices for integrating data from multiple clinical and genomic sources for clinical decision support.

New data sources, technologies, and workflows are being developed and refined to advance clinical decision support and improve patient outcomes, but challenges remain. Research teams today are hampered by the manual effort required to identify, standardize, aggregate, and interpret data. These manual workflows may be manageable during the development of precision medicine programs, but quickly lead to concerns around scaling to meet increasing demand and greater patient numbers.

View this webcast to hear Mayo Clinic’s Research Scientist Jan Egan discuss the value and complexities of compiling data from multiple clinical and genomic sources for clinical decision support. Dr. Egan also shares experiences with standardizing and automating this effort to help clinical and scientific staff in clinical decision support and reporting.

Key takeaways for attendees:

·       An understanding of what data can be used for which decisions with sample use cases

·       Real-world case study insight and best practices for building an environment to leverage omics data for clinical decisions

·       Practical tips for evaluating and selecting a clinical decision support solution

Sponsored by

Assistant Professor of Planetary Science,
Johnson Biosignatures Lab

Postdoctoral Fellow, Johnson Biosignatures Laboratory 

Chair, ABRF Metagenomics Research Group and Extreme Microbiome Project & Manager, Massively Parallel Sequencing Facility, University of Vermont Cancer Center

This webinar discusses the findings of a recent effort to sequence microbial communities in the Dry Valleys of Antarctica, one of the world's most extreme environments.

Receding lakes within the Dry Valleys of Antarctica provide a unique opportunity to study the effects of prolonged desiccation on microbial composition and function. Buried upslope from these lakes are desiccated microbial mats that inhabited the larger paleolakes thousands of years ago. These ancient mats hold insights into adaptations of life to past Antarctic conditions and also present an opportunity to explore the persistence of life in extremely harsh conditions. 

Our panelists share the details of this work. After collecting samples from three Dry Valleys, they extracted DNA using a gentle lysis technique to preserve long reads and a polyenzymatic treatment, developed by the Extreme Microbiome Project, to maximize yields from different cell types. They also recovered RNA from a subset of our paleomat samples. The results of the study demonstrate that cells appear to persist over timescales spanning thousands of years, with implications for our understanding of cell biology, Antarctic microbiology and biogeography, and the limits of life in arid environments.

Viewer can expect to learn: 

- Approaches to extremophile microbiology

- Techniques developed by the Extreme Microbiome Project 

- How new methods and new sequencing technologies like MinION and PacBio may help recover long DNA reads

Sponsored by
1:00 pm2018
Sponsored by

Mining Genomic Literature for Variant Interpretation and Gene Panel Design


University of Vermont Health Network

College of Medicine, University of Vermont

Q2 Solutions, a Quintiles Quest Joint Venture


In this webinar, an expert panel discusses how they used a genomic search engine to mine the genomic literature for two key applications: variant interpretation and the development of evidence-based diagnostic gene panels.

Nikoletta Sidiropoulos and David Seward from the University of Vermont College of Medicine first discuss their approach and the tools used to quickly and thoroughly mine the scientific literature to interpret variants in somatic cancer cases.

Next, Victor Weigman from Q2 Solutions presents an evidence-based method that his team used to select the content for gene panels by mining millions of full-text genomic articles to identify disease-gene-variant relationships. Dr. Weigman discusses how he created an evidence-based gene panel in under a week with prioritized literature citations for each biomarker.

Finally, Mark Kiel, founder and chief scientific officer of Genomenon, discusses a comprehensive, evidence-based cancer panel that was produced using automated machine learning techniques. The pan-hematopoetic cancer panel is a comprehensive cancer panel of more than 300 genes supported by specific literature citations from among millions of research publications. Dr. Kiel discusses how his team used the Mastermind Genomic Search Engine software to objectively correlate genes and genetic variants with the quality and frequency of scientific literature citations.

Sponsored by
1:00 pm2018
Sponsored by
Thermo Fisher Scientific

Rethinking Healthcare with Better Tools, More Information, and Deeper Analysis


Founder & CEO, Sema4

This webinar discusses a predictive, multiscale framework that can be used to understand the health of an individual at the molecular, cellular, organ, organism and community scales in order to better diagnose, treat, and prevent disease at a highly personalized level.

One of the primary goals of precision medicine is the aggregation and interpretation of deep, longitudinal patient-specific data in the context of the digital universe of information, using advanced predictive analytics to better diagnose and treat patients, even down to tailoring individualized treatments.

The rapid advance of panomic technologies such as next-generation DNA sequencing and medical imaging technologies, as well as the vast array of wearable, implantable, and environmental sensors, all linked to personal smart devices, are transforming the scale, scope, and depth of data we can generate on patients.

In this webinar, Eric Schadt, Founder and CEO of Sema4 and Dean for Precision Medicine at the Icahn School of Medicine at Mount Sinai, discusses a predictive, multiscale framework his team has developed to better understand diseases such as coronary artery disease, inflammatory bowel disease, diabetes, asthma health, Alzheimer’s disease, cancer, and several other disease areas in addition to wellness.

In this webinar, Dr. Schadt discusses how his team is evolving this framework to accelerate the engagement of big data and predictive models by patients, physicians, healthcare professionals, and researchers in ways that transform how the medical community diagnoses, treats, and prevents disease.

Sponsored by
1:00 pm2018
Sponsored by
Myriad RBM

A Reproducible Immunomonitoring Method for Multi-Center Clinical Studies


Scientific Manager, LabEx Milieu Interieur, Institut Pasteur, Paris

This webinar discusses a standardized whole-blood culture and stimulation system and its application to a range of multi-center immune response studies.

Our speaker, Darragh Duffy, Scientific Manager of the LabEx Milieu Interieur consortium at the Institut Pasteur, shares details of several projects using the TruCulture whole-blood syringe-based system, which permits point-of-care standardized immune stimulation.

Dr. Duffy's team recently completed a multi-center clinical study in seven Federation of Clinical Immunology Societies (FOCIS) Centers of Excellence across Europe to directly compare TruCulture to conventional peripheral blood mononuclear cell (PBMC) methods. The study found that the ex vivo TruCulture procedure preserved physiological cellular interactions to more accurately reflect the complexities of the human immune system.

Dr. Duffy also shares how his team has applied TruCulture stimulation to the 1,000-donor cohort of the Milieu Interieur consortium, the objective of which is to define the boundaries of a healthy immune response at both the proteomic and transcriptomic level.

Dr. Duffy also discusses a partnership with Myriad RBM to co-develop the 13-analyte OptiMAP Luminex panel to enable the dissection of intrinsic (age, sex), genetic, and environmental factors to diverse immune stimuli at the population level.

Sponsored by
1:00 pm2017
Sponsored by

Incorporating the AMP Guidelines in Molecular Reporting: Best Practices


Providence Oregon Regional Laboratory & Earle A. Chiles Research Institute 

The Swedish Cancer Institute & CellNetix Pathology and Laboratories Institute 

N-of-One, Inc.

N-of-One, Inc.

Children’s Hospital of Philadelphia, University of Pennsylvania, Perelman School of Medicine

About one year ago, the Association for Molecular Pathology (AMP), with liaison representation from the American College of Medical Genetics and Genomics (ACMG), American Society of Clinical Oncology (ASCO), and College of American Pathologists (CAP), released a guideline on reporting somatic cancer variants. 

The AMP guidelines were created to address a specific need: oncologists required a standardized presentation of somatic variants in a diagnostic test report in order to help them quickly understand the results and the importance of each variant in the context of the patient’s disease. Several groups have published “levels of evidence” for the categorization of somatic variants, however the molecular pathology field lacked a single standard. The authors of the AMP guidelines collected and studied reporting schemata from the field and laid out a tier-based reporting system, with defined levels of evidence for each variant’s ability to predict response or resistance to a therapy in the context of a disease, or association with prognostic or diagnostic significance in a disease.  The guidelines were researched and developed by the leading industry organizations without commercial association and are positioned to become an industry standard. 

This webinar focuses on the methodology and benefits of mapping the AMP guideline's Levels of Evidence (LOEs) to somatic variants, addresses the complexity that comes with this process, and explores what industry leaders are doing to address that complexity.

Sponsored by

Manager, Biostatistical Consulting Unit, Cincinnati Children's Hospital Medical Center

Information Security Specialist, Case Western Reserve University

IT Director, BioFrontiers Institute, University of Colorado Boulder

This online seminar, part of the 2017 ABRF Webinar Series, helps lab directors and administrators gain a 101 understanding of file naming, data storage, and data security.

Our panelists discuss protocols for naming data files, how to manage the storage of data – especially large file sizes – and how to protect clinical research data. The seminar includes an update on the National Institutes of Health's policies on data management.

This webinar helps lab managers understand the basics (and challenges) of managing data in a research environment and demonstrates some of the best practices that work well for specific institutions.

Sponsored by

Clinician Scientist & Medical Oncologist,
Institute of Cancer Research, London and the Royal Marsden Hospital

This webinar discusses a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.

Mutations and DNA copy number aberrations (CNAs) are important predictive biomarkers in cancer medicine, but spatial intratumor heterogeneity can hinder accurate cancer profiling from biopsies and cancer evolution alters genomic profiles over time.

Circulating tumor DNA (ctDNA) sequencing may overcome these hurdles by enabling multi-timepoint testing and the detection of subclones that are disseminated in space.

In this webinar, Dr. Marco Gerlinger of the Institute of Cancer Research, London, discusses an approach that combines solution hybrid capture for target enrichment and molecular barcodes for sequencing error correction. This customizable ultra-sensitive ctDNA sequencing technology can be applied to 25 ng of ctDNA, a quantity that can usually be obtained from 10-20 ml of blood. Deep sequencing of the target region with over 20,000x depth enables mutation detection in driver gene panels with a sensitivity of up to 0.1%. The analysis of off-target reads allows simultaneous genome-wide CNA profiling.

Sample preparation, sequencing, and data analysis workflows as well as a concordance analysis of ctDNA and tumor sequencing in colorectal cancers are presented in the webinar.

Sponsored by

Senior Director, Division of Advanced Research Technologies, New York University School of Medicine

Assistant Director, Hoglund Brain Imaging Ctr.,University of Kansas Medical Center

In these times of economic constraint and increasing research costs, shared resource cores have become a cost-effective and essential platform for researchers who seek to investigate complex translational research questions. Cores produce significant value that cannot be captured using traditional financial metrics. Benchmarking studies conducted by the Association of Biomolecular Resource Facilities and other organizations indicate that most research cores do not fully recover operating expenses. As such, these “operational losses” represent institutional investment, which, if well planned and managed, produce future returns for the institution’s research community that extend far beyond subsidized pricing.

Current literature indicates that there is no single measure that can provide an accurate representation of the full picture of the return on research investments.

This presentation attempts to provide instruction and examples using the Balanced Score Card (BSC), (Kaplan and Norton), as a tool for assessing the return on investment for research core facilities.

The BSC supplements traditional financial measures with criteria to measure performance in three additional areas — customers, internal business processes, and learning and growth. The presenters discuss and share their experiences on how they have utilized these ROI approaches to streamline their core operations and make sound investment decisions and strategies to further the mission of their institutions and to meet the expectations of their various investors and key stakeholders.

Sponsored by

Assistant Professor, Washington University 

Director, Technical Support, NuGEN

This webinar discusses the role of a newly discovered, brain-enriched form of non-CpG DNA methylation in neural development and disease.

Neurons in the brain must express diverse complements of genes in order to form synaptic connections and execute physiological responses to stimulation. But how is this complex neuronal transcriptome regulated? Do unique mechanisms exist in neurons to control this process?

During the webinar, Harrison Gabel of Washington University describes a study that used chromatin immunoprecipitation-sequencing, RNA-sequencing, and whole-genome bisulfite-sequencing to demonstrate that uniquely high levels of non-CpG methylation in the brain play a critical role in regulating neuron-specific transcriptional programs.

Dr. Gabel and colleagues have further uncovered evidence that this non-CpG DNA methylation is an important binding site for MeCP2, the protein disrupted in the neurological disorder Rett syndrome.

Dr. Gabel describes these and other studies that have used genomic methods to define how methylated CA (mCA) accumulates in neurons, determine the molecular mechanism of transcriptional regulation mediated by mCA and MeCP2, and understand how disruption of this gene-regulatory pathway contributes to neurodevelopmental disease.

Sponsored by
1:00 pm2017
Sponsored by

Validation of a UMI-Powered NGS Panel for Improved Variant Calling


Director, Labsolutions, LLC

Global Product Manager, Qiagen

This webinar discusses the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Targeted NGS panels have been instrumental in advancing the field of cancer genomics by enabling the analysis of hundreds of mutations across many genes in an individual assay.

The biggest challenges, however, to realizing the full benefits of targeted NGS panels are 1) PCR duplicates and errors introduced during the workflow, which result in reduced confidence in calling variants such as single nucleotide variants and indels; 2) low levels of enrichment and sequencing uniformity, which affect the ability to call low-frequency variants; and 3) long turnaround times and high DNA input requirements, which limit the practicality of NGS panels.

These challenges can be overcome by building a robust workflow with short turnaround times that incorporates unique molecular indices (UMIs) to correct for PCR errors and single primer extension (SPE) to enhance uniformity and reduce the DNA input requirements.

During this webinar, Dr. Bernadette Wildemore of Labsolutions discusses the validation of a UMI-powered DNA panel and associated bioinformatics pipelines in high-throughput routine use. Dr. Raed Samara of Qiagen then discusses the benefits of incorporating UMIs and SPE to overcome the current challenges of using targeted NGS panels.

Sponsored by

Director, Proteomics Shared Resource, Herbert Irving Comprehensive Cancer Center; Assistant professor of Dept. Pharmacology, Columbia University Medical Center

Director, Genome Center Proteomics Facility, 
University of California

Director, Proteomics & Mass Spectrometry Facility,
Research Professor, Biochemistry & Molecular Pharmacology
University of Massachusetts Medical School

Professor, Division of Molecular Biology & Human Genetics
Stellenbosch University Faculty of Medicine & Health Sciences

This webinar answers researchers’ most pressing questions about how to gain outstanding research results from proteomic studies

Researchers and clinicians are increasingly adopting proteomics as a go-to method for gaining biological insights and direction. Proteomic core labs are shared resources with the expertise and instrumentation to carry out these specialized studies. Collaboration between researcher and proteomic core combines the expertise and leverages the strengths of both parties. This webinar provides building blocks on which to jumpstart or strengthen this key relationship.

From study design and sample preparation through data analysis, result interpretation, and overall reproducibility, our panelists will answer your essential questions about setting up and carrying out high-quality proteomic studies. This practical insider info will help researchers and cores to work together and effectively move research forward.


About the GenomeWeb ABRF Webinar Series
GenomeWeb and the Association of Biomolecular Resource Facilities are partnering for the second year to produce a series of online seminars highlighting methods, techniques, and instrumentation that support life science research. Special thanks to the series sponsor, PerkinElmer!

For information on other webinars in the series, please click here.


Sponsored by